The thalassemia syndromes (a-and b-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of a-or b-globin chain production results in impaired red blood cell synthesis, anemia, and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis, and dysfunctional iron metabolism has not been investigated in both a-thalassemia carriers (ATC) and b-thalassemia carriers (BTC). Here, we demonstrate that ATC have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, BTC have several hematological parameters significantly different from controls, including increased soluble transferrin receptor and erythropoietin levels. These changes in both groups suggest an altered balance between erythropoiesis and iron metabolism. The index sTfR/log ferritin and (hepcidin/ferritin)/sTfR are, respectively, increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we showed in this study, for the first time in the literature, that thalassemia carriers have altered iron metabolism and erythropoiesis.
Adult hemoglobin is a heterotetramer composed of two a-globin chains and two b-globin chains (a2b2), each of which contains a heme molecule capable of binding oxygen and facilitating oxygen transport. Thalassemias are a group of hereditary blood disorders characterized by anomalies in the synthesis of a-or b-chains of hemoglobin called a-thalassemia and b-thalassemia, respectively. Together with sickle cell anemia, the thalassemias are the most common inherited disorders of hemoglobin (Hb). Thalassemias are characterized by ineffective erythropoiesis due to the imbalance of globin chain production, resulting in increased apoptosis during erythroblast maturation (1) (2) (3) (4) .
b-thalassemia results from a variety of molecular alterations, including mutations that affect transcription, translation, and mRNA processing as well as gene deletions (5) . Mutations that lead to complete absence of b chains synthesis are defined as b o mutations while those that allow some synthesis of adult hemoglobin are defined as b + mutations. Based on the combination of these mutations and other genetic modifications (such as mutations leading to elevated levels of fetal hemoglobin synthesis), patients may require only periodic and intermittent red blood cell (RBC) transfusion (b-thalassemia intermedia), or chronic RBC transfusion (b-thalassemia major) (5) . Individuals with single heterozygous mutations are considered carriers not requiring treatment.
Deletion or conventional mutations in a-globin genes (a2 and a1) lead to a spectrum of phenotypes, ranging from practically asymptomatic, a-thalassemia carrier, in which one of four a-globin genes is missing, to lethal hydrops fetalis, in which all of the four genes are defective causing death in uterus or shortly after birth (5) .
Patients with different thalassemia syndromes live in Mediterranean countries, South-East Asia, Africa, the Middle East, and the Indian subcontinent, where thalassemia carriers account for more than 20% of the population (6) . Due to the frequency of immigration from these regions in recent decades, the incidence of the thalassemias has increased also in other geographical areas (7) (8) (9) .
In particular, in southeastern Brazil, a frequency of 1.3% of b-thalassemia trait carriers (BTC) was reported in the general population (10), while a-thalassemia trait carriers (ATC), determined by a 3.7-kb DNA deletion (-a 3.7 /aa), varied from 20 to 25% in Brazil's African descents (11) and 9 to 12% in general population. Previous studies have shown that the -a 3.7 is the most frequent a-globin gene deletion in Brazil (12) (13) (14) (15) .
Iron metabolism and erythropoiesis are intrinsically linked, as erythropoiesis requires the coordinated biosynthesis of heme and globin chains to produce Hb during differentiation of erythroid precursor. Erythropoietin (EPO) is increased under conditions that required increased RBC synthesis (16) . The soluble transferrin receptor (sTfR) concentration is increased in patients with expanded erythropoiesis, including those with hemolytic anemias, myelodysplastic syndromes, and those receiving erythropoietic stimulating agents (17) . sTfR is also increased in BTC (18) .
Although hepcidin concentration is increased in conditions of primary iron overload, diseases of concurrent anemia and iron overload (i.e., increased and ineffective erythropoiesis) are associated with relatively suppressed hepcidin levels (16, (19) (20) (21) . Several recent studies suggest that growth differentiation factor 15 (GDF15) might not be the main factor secreted during increased and ineffective erythropoiesis to inhibit hepcidin synthesis (22) (23) (24) . However, GDF15 can be utilized to evaluate the degree of ineffective erythropoiesis (23, 24) .
Concurrent analysis of these parameters can be used to evaluate the relationship between markers of erythropoiesis and iron metabolism. The ratio of serum hepcidin to ferritin (hepcidin/ferritin) can be utilized as an index of hepcidin response to iron load (25) , while the ratio of serum sTfR to ferritin (sTfR/log ferritin) can be used to estimate functional iron requirement (26) . Moreover, the ratio of all three parameters [(hepcidin/ferritin)/sTfR] can be utilized to explore and quantify the opposing forces (i.e., iron availability and erythropoietic activity) regulating hepcidin synthesis and iron absorption in the absence of inflammatory stimuli (27) .
In this study, we investigate the relationship between degree of anemia, increased and ineffective erythropoiesis, and iron sensing in patients with a-and b-thalassemia silent carriers. To accomplish this goal, we evaluate the correlations between several erythroid and iron-related factors, including serum hepcidin. The purpose of this inquiry is to provide new insight into the balance between iron metabolism and erythropoiesis in relatively mild anemias and to explore new clinically relevant measures to characterize patients with these and other anemia-related conditions.
Patients and methods

Ethics approval
The Faculty of Pharmaceutical Sciences of Ribeirao Preto from University of Sao Paulo (FCFRP/USP) Ethics Committee approved the study with the agreement of The Clinical Hospital of Medical School of Ribeirao Preto (HC/FMRP/ USP) Ethics Committee. All patients provided written consent in accordance with the current law and Declaration of Helsinki.
Subjects
Adult subjects were recruited as unselected group of both first-time and repeat blood donors (RBDs). Samples for analysis were collected prior to blood donation at the Clinical Hematology Laboratory (FCFRP-USP, Ribeirao Preto, Brazil).
Control, RBD, and ATC groups. The study subjects were first screened for a-thalassemia deletions (28) , and of 177 screened, 15 (8.47%) had one a-gene deletion (-a 3.7 /aa). Among those silent carriers for -a 3.7 , 1 patient was excluded due to a presumed infection, evidenced by elevated C-reactive protein (CRP) and white blood cell (WBC) count. Thus, 14 patients were selected to form the ATC group.
Of the remaining 162 blood donors screened, 51 met inclusion criteria: Hb greater than 13.0 g/dL for men and 12.0 g/dL for women (29) ; normal RBC count, ferritin, serum iron, % transferrin saturation (%Tsat), total iron-binding capacity (TIBC), and sTfR; CRP <3.0 mg/L; absent evidence of hemoglobinopathies or other clinical disorders that alter iron metabolism (e.g., inflammatory and acute or chronic infections); and no presence of dysmetabolic syndrome. These 51 subjects were divided in two groups, Control (n = 28) and RBD (n = 23). The RBD was defined as those donating blood at least twice in the year prior to study enrollment.
BTM and BTC groups. Adult patients with BTM (n = 27) and BTC (n = 20) were from previously identified and regularly followed patients in the Hemoglobinopathies Clinic (Ribeirao Preto, HC/FMRP-USP, Brazil). In patients with BTM, blood was collected immediately prior to RBC transfusion.
Analysis of mutations
Genomic DNA was extracted using AxyPrepTM Blood Genomic DNA Miniprep Kit (nucleic acid Purification kit), Axygen Biosciences. The conventional RT-PCR protocol was used to detect the most common a-thalassemia deletion -a 3.7 in southeast Brazil and identify ATC individuals (28) . Moreover, to assess participants for any unexpected hemoglobinopathies, hemoglobin electrophoresis using acetate cellulose paper at alkaline pH (pH 8.6) was performed and gene analysis was carried out for BTC and patients with BTM.
Laboratory analysis
Samples were tested for hematological parameters (Micros ABX 60), serum iron, TIBC, and %Tsat by the colorimetric method (Pointe Scientific, Inc., Canton, MI, USA), ferritin and high-sensitive CRP by immunoassay (Immulite 1000 kits, Siemens, Camberley, UK), sTfR, EPO, and GDF15 (R&D System, Minneapolis, MN, USA), and hepcidin (Intrinsic LifeSciences, La Jolla, CA, USA) by ELISA.
Normal values and definitions
Suominen et al. (30) suggested that the normal ferritin serum levels range is 22-203 lg/L and sTfR concentration range is 1.15-2.75 mg/L. For serum iron, TIBC and %Tsat, the manufacturer suggests each study to perform the normal range. For our study, the normal ranges we established for serum iron, TIBC, and %Tsat were 60-170 lg/dL, 160-400 lg/dL, and 20-60%, respectively. For CRP, the expected upper normal limit for healthy individuals established in the literature was <3 mg/L; however, a study performed on 100 healthy volunteers yielded a median of 1.4 mg/L and an upper 97.5th percentile of 11 mg/L (31). The reference range for EPO serum assay established by manufacturer in 123 normal individuals from the Minneapolis/St. Paul, Minnesota area was 3.3-16.6 mIU/mL, in our study, the range in 46 healthy adults from the region of Ribeirao Preto, Brazil area was 0.5-13.4 mIU/mL, mean 4.8 mIU/mL. Tanno et al. (22) suggested that GDF15 levels in normal individuals were between 200 and 1150 pg/mL. A well-validated assay that allows hepcidin quantification reported in a previous study indicated that the 5th-95th percentile for serum hepcidin concentrations in normal adult men were 29-254 ng/mL (n = 65) and 17-286 ng/mL in adult women (n = 49), with median concentrations 112 ng/mL in men and 65 ng/mL in women (P < 0.001) (32) .
Statistical considerations
Statistical analyses of the results were performed by GraphPad Prism version 5.02 (GraphPad Software, Inc., La Jolla, CA, USA). Due to the skewed distributions, the parameters were log-transformed to approximate a normal distribution and parametric analyses were conducted. For all variables, geometric means, medians, minimum and maximum, standard errors, and standard deviations were calculated. Due to gender differences, we conducted stratified analyses. Pearson correlation coefficients were generated to assess relationships between indices. One-way ANOVA and post-test Dunnett's multiple comparison tests were used for group comparisons of the biological parameters. Data are presented as mean AE 95% confidence interval (CI), and P < 0.05 was considered statistically significant.
Results
Control vs. RBD
Controls were derived from the general blood donor pool, so first we compared first-time blood donors and RBD. We did not observe any statistical difference comparing various parameters between controls and RBD (Suppl. 1). In addition, the expected correlation between hepcidin and ferritin previously reported (27, (33) (34) (35) is only maintained in Control group (n = 28); ATC indicates a-thalassemia carriers (n = 14); BTC indicates b-thalassemia carriers (n = 20); BTM, b-thalassemia major (n = 27); RBDs, repeat blood donors (n = 23); GDF15, growth differentiation factor 15; EPO, erythropoietin, and sTfR, soluble transferrin receptor. The statistical analyses were performed using Pearson's correlation test, significant P is shown as bold.
controls (Table 1) . Hepcidin/ferritin is a parameter correlates well with iron absorption (36) . These observations suggest that multiple blood donations alter the typical relationship between parameters of iron metabolism (37) . For this reason, only first-time donors were used as controls in this study.
Silent carriers of a-thalassemia
Although the hematological changes in the ATC group are considered in the normal range, the mean corpuscular volume (MCV) and the mean corpuscular hemoglobin (MCH) are significant different from controls ( Table 2 ), suggesting that individual with this profile should be investigated to evaluate if carriers of a single a-globin mutation. ATC also showed significant increased in soluble transferrin receptor levels and decreased of hepcidin levels ( Table 3 ). These taking together suggest that even a deletion of one a-gene shows an increased erythropoietic activity reducing hepcidin levels so the iron absorption can be raised to keep the balance between hemoglobin levels and iron status. These results suggest a measurable compensatory increase in erythropoiesis and its consequent suppressive effect on hepcidin synthesis.
b-thalassemia minor b-thalassemia carriers group showed significant differences for all hematological parameters ( Table 2 ). The rise in the RBC count (Table 2) due erythropoiesis expansion suggests an attempt to compensate for reduced Hb concentration due to lower MCV and MCH. The elevated erythropoietic activity is reflected by increased serum levels of sTfR and EPO (Table 3 ).
b-thalassemia major
In the BTM group, all hematological parameters except mean corpuscular hemoglobin concentration (MCHC) are significantly different. While RDW is increased, all the Control group (n = 28); ATC indicates a-thalassemia carriers (n = 14); BTC indicates b-thalassemia carriers (n = 20); BTM, b-thalassemia major (n = 27); RBC, red blood cells count; Hb, hemoglobin; Hct, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration and RDW, red cell distribution width. The statistical analyses were performed using oneway ANOVA and Dunnett's multiple comparison post-test. * P < 0.05, * * P < 0.01, * * * P < 0.001, relative to controls. Control group (n = 28); ATC indicates a-thalassemia carriers (n = 14); BTC indicates b-thalassemia carriers (n = 20); BTM, b-thalassemia major (n = 27); TIBC, total iron-binding capacity; Tsat, transferrin saturation; sTfR, soluble transferrin receptor; GDF15, growth differentiation factor 15, and EPO, erythropoietin. The statistical analyses were performed using oneway ANOVA and Dunnett's multiple comparison post-test.
others are decreased relative to controls (Table 2 ). In addition, all the biochemical parameters, except for TIBC and hepcidin, are significantly higher relative to controls (Table 3) . However, as previously shown, reduced hepcidin/ ferritin indicates that hepcidin levels are disproportionally low relative to the degree of iron overload (25, 38, 39) . Furthermore, we demonstrate that hepcidin concentrations in patients with BTM are within the reference values but mean (hepcidin/ferritin)/sTfR (Table 3) is markedly reduced in all patients.
sTfR/log ferritin ratio and sTfR levels
The sTfR/log ferritin ratio can distinguish storage iron depletion, iron deficiency erythropoiesis, and iron deficiency anemia when ferritin levels are also low (30) . However, when ferritin levels are normal or increased, the sTfR levels reflect the erythropoietic activity (27, 36, 39) . All study groups showed a significant raise for sTfR levels and index sTfR/log ferritin proportional to the severity of their deletion/mutation ATC < BTC < BTM (Table 3) .
The association of hepcidin, ferritin, and sTfR in the formula (hepcidin/ferritin)/sTfR was useful to distinguish the different groups showing a significant reduction of this index proportional to the severity of their deletion/mutation ATC > BTC > BTM (Table 3) . The distribution of the study groups plotting the hepcidin/ ferritin ratio against sTfR can be viewed in the Fig. 1 . While controls are in the lower left corner, thalassemia carriers such as ATC and BTC appear dislocated to the right as 'normal hepcidin to ferritin ratio-moderately high sTfR' with the sTfR concentration reflecting the raise in the erythropoietic activity. However, patients with BTM are in the upper right corner due to 'low hepcidin to ferritin ratio-high sTfR' and reflecting a high erythroid demand associated with increased iron absorption, characteristic of iron-overloading anemia.
Discussion
We showed in this study, for the first time in the literature, that thalassemia carriers have altered iron metabolism and erythropoiesis. These aspects were not addressed in any other study with thalassemia carriers, as far as we know. Carriers of a-thalassemia (with three function a-genes) known as silent carriers are reported to have no hematological alterations (40) (41) (42) . Carriers of b-thalassemia with one normal b-gene are reported to have no hematologic abnormalities to borderline asymptomatic anemia with microcytosis and hypochromia (43) .
Our study suggests that even a deletion of one a-gene shows an increased erythropoietic activity with reduced hepcidin levels so the iron absorption can be raised to keep the balance between hemoglobin levels and iron status. These results suggest a measurable compensatory increase in erythropoiesis and its consequent suppressive effect on hepcidin synthesis.
In carriers of b-thalassemia, the rise in the RBC count (Table 2 ) due to erythropoiesis expansion suggests an attempt to compensate for the reduced Hb concentration due to lower MCV and MCH. The elevated erythropoietic activity we found in this population is reflected by increased serum levels of sTfR and EPO (Table 3) .
Interestingly, patients with BTM show increased sTfR, EPO, sTfR/log ferritin, and GDF15 ( Table 3 ), suggesting that, despite RBC transfusions, expanded erythropoiesis is likely present but ineffective (16) .
We also evaluate whether correlations among hepcidin, ferritin, and sTfR are useful to estimate the degree of iron absorption as a consequence of the multiple factors controlling hepcidin synthesis in the absence of inflammation, that is, iron storage and erythropoietic activity. Based on our observations, we combine parameters related to iron metabolism such as hepcidin and ferritin with sTfR, a marker of erythropoietic proliferation, and determine an equation to assist clinicians with the diagnosis of severe thalassemias and to discriminate the thalassemia carriers from controls. The association of hepcidin, ferritin, and sTfR in the formula (hepcidin/ferritin)/sTfR was useful to distinguish the study groups showing a significant reduction proportional to the severity of their deletion/mutation ATC > BTC > BTM (Table 3 ). This could be helpful to monitor the appropriateness of iron absorption and potential issues related to accumulation of iron over time and worsening of erythropoiesis. Several studies have investigated the correlation between erythropoiesis and iron metabolism in patients with BTM (16, 25, 44) . However, the molecular mechanism(s) responsible for communicating iron demand for erythropoiesis remain incompletely understood.
Conclusion
There are two main conclusions of this study. First, ATC and to a greater degree BTC showed an altered balance between iron absorption/storage and erythropoiesis. Although a cross-sectional analysis such as this is not designed to determine potential accumulation of ill effects over time, evidence provided here suggests that patient care may benefit from prospective monitoring of ATC and BTC to evaluate whether abnormalities in erythropoiesis and increased iron absorption negatively affect their health over time, such as iron overload. Second, patients with BTM demonstrate features consistent with ineffective erythropoiesis (i.e., increased erythroid cell proliferation and cell death as suggested by increased sTfr1 and GDF15 levels), and abnormal iron metabolism (Table 3) , despite transfusion to Hb levels of 8-10 g/dL, suggesting that additional therapy to complement transfusion and management of iron metabolism are necessary to further benefit patient health. Novel therapeutic agents, such as apotransferrin, Jak2 inhibitors, antisense oligonucleotides to target TMPRSS6, minihepcidins, and hypoxia-inducible factor 2-alpha (HIF2a) antagonists to reduce the level of ineffective erythropoiesis and/or decrease iron absorption are currently being developed in this direction (45) (46) (47) (48) (49) .
